[
  {
    "ts": null,
    "headline": "Refresh Releases First of its Kind Eye Drop for Dry Eyes",
    "summary": "AbbVie (NYSE: ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada. The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture.",
    "url": "https://finnhub.io/api/news?id=736a3483e30198b640b6ae1e0aecd0537c004f7340fd4109aceaff2621820dd4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752269700,
      "headline": "Refresh Releases First of its Kind Eye Drop for Dry Eyes",
      "id": 135887046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV), announced today the availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada. The new, preservative-free eye drop is designed to provide rapid and long-lasting relief from dry eyes with the inclusion of natural omega-3 oil that helps lock in moisture.",
      "url": "https://finnhub.io/api/news?id=736a3483e30198b640b6ae1e0aecd0537c004f7340fd4109aceaff2621820dd4"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 13",
    "summary": "Read our weekly summary for companies which changed their dividends, stocks with upcoming ex-dividend dates, and companies with upcoming pay dates.",
    "url": "https://finnhub.io/api/news?id=5b34acd3126724038a16d4d87babf7ac15d7848a2942daa99152d2b8c81edf6c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752258545,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of July 13",
      "id": 135885054,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Read our weekly summary for companies which changed their dividends, stocks with upcoming ex-dividend dates, and companies with upcoming pay dates.",
      "url": "https://finnhub.io/api/news?id=5b34acd3126724038a16d4d87babf7ac15d7848a2942daa99152d2b8c81edf6c"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=76e6acfa23f6448e83676c187ef1f40cf070d09723711a017b382e880cb2c583",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752251460,
      "headline": "AbbVie Inc. stock underperforms Friday when compared to competitors",
      "id": 135949314,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=76e6acfa23f6448e83676c187ef1f40cf070d09723711a017b382e880cb2c583"
    }
  },
  {
    "ts": null,
    "headline": "ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?",
    "summary": "AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.",
    "url": "https://finnhub.io/api/news?id=34a4b433845c069154092e555ae20c3cf368a16b00d08767dbc941be64af250b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752242400,
      "headline": "ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?",
      "id": 135883478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.",
      "url": "https://finnhub.io/api/news?id=34a4b433845c069154092e555ae20c3cf368a16b00d08767dbc941be64af250b"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech: A Fast-Expanding Biosimilar Concern",
    "summary": "Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt concerns, and tariff challenges.",
    "url": "https://finnhub.io/api/news?id=18e00e0ea56521085f094ca75a7d197bbe2781e2c3c86c5b423335ca89a4e85a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752238167,
      "headline": "Alvotech: A Fast-Expanding Biosimilar Concern",
      "id": 135882391,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1456995360/image_1456995360.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Alvotech stock has dropped despite strong fundamentals and rapid sales growth. Read about ALVO's projected revenue, debt concerns, and tariff challenges.",
      "url": "https://finnhub.io/api/news?id=18e00e0ea56521085f094ca75a7d197bbe2781e2c3c86c5b423335ca89a4e85a"
    }
  },
  {
    "ts": null,
    "headline": "A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025",
    "summary": "A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025",
    "url": "https://finnhub.io/api/news?id=92280ee03c5624684ef9fc3018a8af2e7565344f273378e454ed35e7fbdca62d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752226440,
      "headline": "A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025",
      "id": 135877910,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=92280ee03c5624684ef9fc3018a8af2e7565344f273378e454ed35e7fbdca62d"
    }
  },
  {
    "ts": null,
    "headline": "IGI and AbbVie sign licence deal for cancer and autoimmune  therapy",
    "summary": "IGI Therapeutics will be entitled to $1.225bn on reaching development milestones and targets.",
    "url": "https://finnhub.io/api/news?id=407e5a5f6e265129fa5e8dff85761e1d3a7dfc160e06b3776da83ab39f213031",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752223123,
      "headline": "IGI and AbbVie sign licence deal for cancer and autoimmune  therapy",
      "id": 135883479,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "IGI Therapeutics will be entitled to $1.225bn on reaching development milestones and targets.",
      "url": "https://finnhub.io/api/news?id=407e5a5f6e265129fa5e8dff85761e1d3a7dfc160e06b3776da83ab39f213031"
    }
  },
  {
    "ts": null,
    "headline": "Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments",
    "summary": "Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic treatments like monoclonal antibodies and immunomodulators. Market segmentation by drug class includes Anti-TNF α agents and interleukin antagonists, each offering distinct benefits. North America leads the market with established healthcare infrastructure. Key growth drivers are the rising incidence",
    "url": "https://finnhub.io/api/news?id=c1ac3bb63e87f8a640eb5ce87d00de4c05358a5d56e3d49fcd1edd8e902cdb8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752221100,
      "headline": "Ulcerative Colitis Drug Market Analysis and Forecast, 2025-2035 | Anti-TNF a Agents and Interleukin Antagonists Spearhead Therapeutic Developments",
      "id": 135877171,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Ulcerative colitis, a chronic inflammatory bowel disease, presents treatment challenges due to its variable symptoms and unpredictable flare-ups. The global market is set to grow, driven by biologic treatments like monoclonal antibodies and immunomodulators. Market segmentation by drug class includes Anti-TNF α agents and interleukin antagonists, each offering distinct benefits. North America leads the market with established healthcare infrastructure. Key growth drivers are the rising incidence",
      "url": "https://finnhub.io/api/news?id=c1ac3bb63e87f8a640eb5ce87d00de4c05358a5d56e3d49fcd1edd8e902cdb8e"
    }
  },
  {
    "ts": null,
    "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
    "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
    "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220860,
      "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
      "id": 135876885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
      "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571"
    }
  },
  {
    "ts": null,
    "headline": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
    "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
    "url": "https://finnhub.io/api/news?id=6f77dcacefc94745fb5ff0c50afcfdd618a84e09c61aae803547dbac3a658950",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220500,
      "headline": "What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill",
      "id": 135877175,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "A steady dose of quality companies will keep your portfolio growing big and strong.",
      "url": "https://finnhub.io/api/news?id=6f77dcacefc94745fb5ff0c50afcfdd618a84e09c61aae803547dbac3a658950"
    }
  },
  {
    "ts": null,
    "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal",
    "summary": "(Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment.  The stock was the top percentage gainer on the Nifty Pharma index, which traded 1.1% higher compared to a 0.4% loss in the benchmark Nifty 50.  AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal.",
    "url": "https://finnhub.io/api/news?id=a003e944217049a86ffc73eeb15a92154ad03d119213ac2ba4295a8baca9866c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752206106,
      "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal",
      "id": 135866569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "(Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after its unit signed a licensing deal with U.S. peer AbbVie for its early-stage blood cancer treatment.  The stock was the top percentage gainer on the Nifty Pharma index, which traded 1.1% higher compared to a 0.4% loss in the benchmark Nifty 50.  AbbVie will get the exclusive rights to develop and commercialise ISB 2001 in North America, Europe, Japan and Greater China, according to the deal.",
      "url": "https://finnhub.io/api/news?id=a003e944217049a86ffc73eeb15a92154ad03d119213ac2ba4295a8baca9866c"
    }
  },
  {
    "ts": null,
    "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer licensing deal",
    "summary": "Shares of India's GlenmarkPharmaceuticals jumped 10% to a record high on Friday,a day after its unit signed a licensing deal with U.S. peerAbbVie for its early-stage blood cancer treatment. ...",
    "url": "https://finnhub.io/api/news?id=f366defe1fd227476d0a189224dfae201fa9be126f5ea4617183c9a6b8f28724",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752195789,
      "headline": "India's Glenmark Pharma soars 10% to record high on AbbVie cancer licensing deal",
      "id": 135865305,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Shares of India's GlenmarkPharmaceuticals jumped 10% to a record high on Friday,a day after its unit signed a licensing deal with U.S. peerAbbVie for its early-stage blood cancer treatment. ...",
      "url": "https://finnhub.io/api/news?id=f366defe1fd227476d0a189224dfae201fa9be126f5ea4617183c9a6b8f28724"
    }
  }
]